Response to Hydralazine-Valproate in a Patient with Mycosis Fungoides | Zendy

Alfonso DueñasGonzález | Zendy; María Teresa Vega Rodríguez | Zendy; Déborah Martı́nez-Baños | Zendy; Linda GarcíaHidalgo | Zendy; Pedro Sobrevilla | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Response to Hydralazine-Valproate in a Patient with Mycosis Fungoides

Author(s) -

Alfonso DueñasGonzález,

María Teresa Vega Rodríguez,

Déborah Martı́nez-Baños,

Linda GarcíaHidalgo,

Pedro Sobrevilla

Publication year - 2010

Publication title -

case reports in medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.2

H-Index - 20

eISSN - 1687-9627

pISSN - 1687-9635

DOI - 10.1155/2010/657579

Subject(s) - mycosis fungoides , medicine , histone deacetylase , hydralazine , cancer research , epigenetics , histone , dna methylation , demethylating agent , pharmacology , dermatology , dna , gene , biology , lymphoma , genetics , gene expression , blood pressure

Histone deacetylase (HDAC) inhibitors have shown significant activity in the treatment of cutaneous T-cell lymphomas (CTCL). The epigenetic alterations of CTCL not only are limited to altered histone acetylation but also include aberrant DNA gene methylation hence, the combination of an HDAC inhibitor with a DNA demethylating agent is a promising therapy to be tested. Here we report a mycosis fungoides patient having a dramatic response to hydralazine and valproate, two repositioned drugs as HDAC and DNA methylation inhibitors, respectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research